Research
Hormonal
Asprosin may have a protective role in cardiovascular disease by preventing cardiomyocyte apoptosis and improving mesenchymal stromal cell function in myocardial infarction models.
Current research indicates asprosin might protect heart cells from damage in diabetic conditions and improve stem cell therapy outcomes for heart attacks. However, this is still in early research stages. For now, managing cardiovascular risk factors remains the standard of care.
LimitedSupportsLOW confidence
Conversely, asprosin may play a protective role in the heart. Asprosin significantly inhibits malondialdehyde (MDA) and reactive oxygen species (ROS) generation in glucose-induced apoptotic mouse cardiomyocytes (MCMs), and accordingly rescues these cells... pretreatment of asprosin on MSCs augmented homing of these cells, improved myocardial ejection function, and reduced myocardial remodeling after MI.
Why this rating
Based on in vitro and mouse models; human clinical data is limited to correlation with disease severity.
Source
Asprosin: A Novel Player in Metabolic Diseases
Mingyang Yuan et al. · Frontiers in Endocrinology · 2020
DOI 10.3389/fendo.2020.00064
narrative_reviewCited 169×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Elevated circulating asprosin levels are positively associated with insulin resistance, type 2 diabetes, and obesity in adult populations, suggesting asprosin acts as a biomarker for metabolic dysregulation.Moderate
- Asprosin promotes hepatic glucose production (gluconeogenesis) and stimulates appetite (orexigenic effect) via central and peripheral signaling pathways, although the reproducibility of these effects is controversial due to reagent quality issues.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →